Consensus $49.79M. Sees 2024 nonGAAP adjusted EBITDA $20M-$23M from $22M-$26M.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- AQST Upcoming Earnings Report: What to Expect?
- Aquestive Therapeutics Advances Non-Invasive Epinephrine Treatment
- Aquestive Therapeutics reports data for Anaphylm Sublingual Film
- Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study
- Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET